Form 38.5 (a) - Aon Plc
FORM 38.5(a)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED
INTERMEDIARY STATUS AND DEALING IN A CLIENT-SERVING CAPACITY
1. | KEY INFORMATION |
| Merrill Lynch International | |
| Aon PLC | |
| Common - IE00BLP1HW54 | |
| 03/07/2020 |
2. | DEALINGS (Note 2) |
(a) | Purchases and sales |
Total number of relevant securities acquired | Highest price paid (Note 3) | Lowest price paid (Note 3) |
N/A | N/A | N/A |
Total number of securities disposed | Highest price received (Note 3) | Lowest price received (Note 3) |
N/A | N/A | N/A |
(b) | Derivatives transactions (other than options transactions) |
Product name, | Nature of transaction | Number of relevant securities | Price per unit |
N/A | N/A | N/A | N/A |
(c) | Options transactions in respect of existing relevant securities |
(i) | Writing, selling, purchasing or varying |
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 5) | Exercise price | Type, e.g. American, European etc | Expiry date | Option money paid/ received per unit (Note 3) |
N/A | N/A | N/A | N/A | N/A | N/A | N/A |
(ii) | Exercising |
Product name, | Number of securities | Exercise price per |
N/A | N/A | N/A |
3. | OTHER INFORMATION |
Agreements, arrangements or understandings relating to options or derivatives |
Full details of any agreement, arrangement or understanding between the person | |
87 shares returned |
Date of disclosure | 06/07/2020 |
Contact name | Tolu Tade |
Telephone number | +44207 996 3410 |
Name of offeree/offerer with | Willis Towers Watson PLC |
Nature of connection(Note 6) | Advisor to - Willis Towers Watson PLC |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.